Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company for updated Phase 1/2 Results for SB-525. This is an investigational Hemophilia-A gene therapy that showed sustained increased Factor VIII Levels with no reported...
bad data today was release that cause the trend to reverse would be looking for the that 38.2% fib retrace to next area of supply, see if demand picks up there or it will fall further.
one of martin shkreli's old picks (aka pharma bro)
looks like it could be breaking up here look at the CS bo the cloud with volume and fisher support
manage your risk
gl hf
xoxo
snoop
If this supply zone can be taken out by bulls, buyers will be starting to take control as supply zones are starting to get destroyed and demand zones are being created.
If the trend does change, can start looking for long orders.
Sangamo Therapeutics, Inc. is a company that develops genomic therapies, using genome editing, gene therapy, gene regulation, and cell therapy. It's an interesting addition to your swing trading portfolio, specially now that it is ready to start trending up after being accumulated after enduring an extensive correction, now trading at a 40% discount from recent...
SGMO has stochastic divergence on channel line support. Look for this to turn up more before getting in.
Buy: 12.66
Target: 13.50 - 14.86 (6.64% - 17.38%)
Buying off the trend line from $4.25 - $4.35. Stop loss at $4.15. Target is resistance around $5.00. If it breaks and holds $5+, it may have enough gas to go higher.
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
SGMO
